Inspire

Akpek EK, Vittitow J, Verhoeven RS, Brubaker K, Amar T, Powell KD, Boyer JL, Crean C. Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation. J Ocul Pharmacol Ther. 2009 Oct;25(5):433-439. Article in PDF

Navratil T, Schaberg A, Mathews D, Deans C, Durham T, Accurso FJ. Pharmacological treatment of CF: Lessons learned from a phase 3 clinical trial. Poster presented at the 23rd Annual North American Cystic Fibrosis Conference. 2009 Oct 15-17; Minneapolis, Minnesota. Poster in PDF

Mospan AR, Durham TA, Schaberg AE, Accurso FJ. Effects of denufosol on sinusitis-related complaints in a phase 3 trial in cystic fibrosis patients. Poster presented at the European Cystic Fibrosis Society (ECFS) Annual Conference. 2009 Jun 10-13; Brest, France. Poster in PDF

Accurso FJ, Durham TA, Schaberg AE. Relationship between pulmonary exacerbations and lung function decline in a six month placebo-controlled trial of denufosol. Poster presented at the European Cystic Fibrosis Society (ECFS) Annual Conference. 2009 Jun 10-13; Brest, France. Poster in PDF

Fulcher E, Herbold M, Brown A, Pelz N, Slade D, Lampe J, Navratil T. Novel rho kinase inhibitors are potent and efficacious anti-inflammatory agents: an emerging role for rho kinase 1. Poster presented at the American Thoracic Society (ATS) 2009 International Conference . 2009 May 15-20; San Diego, California, USA. Poster in PDF

Moss RB, Anbar RD, Wilmot RW, Barnes M, Schaberg AE, Durham TA, Accurso FJ. Phase 3 study of denufosol tetrasodium for the treatment of cystic fibrosis. Poster presented at the American Thoracic Society (ATS) 2009 International Conference . 2009 May 15-20; San Diego, California, USA. Poster in PDF

Navratil T, Wells G, Bodnar W, Crean C, Lampe J, Peterson W. Novel rho kinase inhibitors with bronchodilator and anti-inflammatory properties engineered for oral versus inhalation delivery. Poster presented at the American Thoracic Society (ATS) 2009 International Conference . 2009 May 15-20; San Diego, California, USA. Poster in PDF

Brown A, Fulcher E, Aycock M, Slade D, Pelz N, Sorensen S, Navratil T. Anti-proliferative properties of novel multi-kinase inhibitors. Poster presented at the American Thoracic Society (ATS) 2009 International Conference . 2009 May 15-20; San Diego, California, USA. Poster in PDF

Sorenson S, Lee F, Boyer J, Peterson W, Lampe J, Navratil T. Novel potent rho kinase inhibitors fully reverse bronchoconstriction in isolated rat trachea rendered nonresponsive to b-agonists. Powerpoint presentation at the American Thoracic Society (ATS) 2009 International Conference . 2009 May 15-20; San Diego, California, USA.

Wells G, Fulcher E, Navratil T, Lampe J, Anderson S, Peterson W. The bronchodilator property or anti-inflammatory property of novel rho kinase inhibitors is sufficient to reduce airway hyperreactivity. Poster presented at the American Thoracic Society (ATS) 2009 International Conference . 2009 May 15-20; San Diego, California, USA. Poster in PDF

Vittitow JL, Parham AJ, BodnarWM, Crean CS. Pharmacokinetic modeling of azithromycin in rabbit eyelids following topical ocular administration of AZASITE^®. Poster presented at the Association for Research in Vision & Ophthalmology (ARVO) 2009 Annual Meeting. 2009 May 3-7; Fort Lauderdale, Florida, USA. Poster in PDF

Boyer JL, Bodnar W, Crean CS, Guogas LM. Cell-associated azithromycin confers protection to human corneal epithelial cells from staphylococcus aureus infection. Poster presented at the Association for Research in Vision & Ophthalmology (ARVO) 2009 Annual Meeting. 2009 May 3-7; Fort Lauderdale, Florida, USA.

Guogas LM and Boyer JL. Azithromycin suppresses bacterial lipases expressed by staphylococcus. Poster presented at the Association for Research in Vision & Ophthalmology (ARVO) 2009 Annual Meeting. 2009 May 3-7; Fort Lauderdale, Florida, USA.

Touhey D, Shapiro A, Torkildsen G, Haque R, Zink RC, Kowalski RP, Mah FS, Pflugfelder SC. Efficacy of topical azithromycin ophthalmic solution 1.0% in the treatment of chronic blepharitis patients. Poster presented at the Association for Research in Vision & Ophthalmology (ARVO) 2009 Annual Meeting. 2009 May 3-7; Fort Lauderdale, Florida, USA. Poster in PDF

Stewart WC, Crean CS, Zink RC, Haque R, Hwang DG. Pharmacokinetics of azithromycin and moxifloxacin in human conjunctiva and aqueous humor during and after the approved dosing regimens. Poster presented at the Association for Research in Vision & Ophthalmology (ARVO) 2009 Annual Meeting. 2009 May 3-7; Fort Lauderdale, Florida, USA. Poster in PDF

Foulks GN, Borchman D, Yappert M. Modification of meibomian gland lipids by topical azithromycin. Poster presented at the Association for Research in Vision & Ophthalmology (ARVO) 2009 Annual Meeting. 2009 May 3-7; Fort Lauderdale, Florida, USA.

Romanowski EG, Kowalski RP, Mah FS, Yates KA, Gordon YJ, Shanks RMQ. The development of a novel in vitro efficacy testing method for a cell-associated antibiotic. Poster presented at the Association for Research in Vision & Ophthalmology (ARVO) 2009 Annual Meeting. 2009 May 3-7; Fort Lauderdale, Florida, USA.

Zhou N, Ma P, Li D-Q, Pflugfelder SC. Azithromycin suppresses pro-inflammatory mediators stimulated by a TLR2 ligand zymosan in human corneal epithelial cells. Poster presented at the Association for Research in Vision & Ophthalmology (ARVO) 2009 Annual Meeting. 2009 May 3-7; Fort Lauderdale, Florida, USA.

Jacot JL, Jacot TA, Hahto S, Helis J, Sheppard CJ, Sheppard JD, Jr., Lattanzio FA, Jr., Williams PB. Azithromycin alters ProMMP-2 and TIMP-1 following corneal wounding in an experimental animal model of diabetic ocular complications. Poster presented at the Association for Research in Vision & Ophthalmology (ARVO) 2009 Annual Meeting. 2009 May 3-7; Fort Lauderdale, Florida, USA.

Sadrai Z, Hajrasouliha AR, Chauhan SK, Saban DR, Dastjerdi MH, Dana R. Effect of topical azithromycin on innate immune responses in experimental keratitis Poster presented at the Association for Research in Vision & Ophthalmology (ARVO) 2009 Annual Meeting. 2009 May 3-7; Fort Lauderdale, Florida, USA.

Navratil T, Wells G, Bodnar W, Crean C, Lampe J, Peterson W. Novel rho kinase inhibitors with bronchodilator and anti-inflammatory properties suitable for treatment of respiratory diseases. Poster presented at the Experimental Biology 2009 Meeting in New Orleans, Louisiana, USA. Poster in PDF

Shapiro A, Haque R, Kowalski RP, Mah FS, Pflugfelder SC, Torkisdsen G. Topical azithromycin improves blepharitis signs and symptoms. Powerpoint presentation at the 2009 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting. 2009 Apr 3-8; San Francisco, California, USA. Presentation in PDF

Trattler WB, Kuhn KL, Haque R, Zink RC, Sall KN, Luchs JI. Clinical efficacy of topical azithromycin 1.0% in blepharitis patients. Powerpoint presentation at the 2009 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting. 2009 Apr 3-8; San Francisco, California, USA. Presentation in PDF

Accurso F. A Phase 3 study of denufosol for cystic fibrosis: TIGER-1 results. Powerpoint presentation at the 22nd Annual North American Cystic Fibrosis Conference (NACFC). 2008 Oct 23-25; Orlando, Florida, USA. Presentation in PDF

Crean C, Godin SJ, Cowlen M, Kellerman D. Pharmacokinetics of Denufosol: Results from preclinical studies. Poster presented at the 22nd Annual North American Cystic Fibrosis Conference (NACFC). 2008 Oct 23-25; Orlando, Florida, USA. Poster in PDF

Tian W. Power analysis of ancova and two non-parametric procedures. Poster presented at the 29th Annual Conference of the International Society for Clinical Biostatistics (ISCB). 2008 Aug 17-21; Copenhagen, Denmark. Poster in PDF

Kellerman D, Rossi Mospan A, Engels J, Schaberg A, Gorden J, Smiley L. Denufosol: A review of studies with inhaled P2Y₂ agonists that led to Phase 3. Pulm Pharmacol Ther. 2008 Aug; 21(4): 600-607.

Boyer JL, Brubaker K, Wolff SC, Fulcher EH, Lankford JR, Navratil T. Assessment of antimuscarinic activity of topical and oral antihistamines. Poster presented at the ARVO (Association for Research in Vision & Ophthalmology) 2008 Annual Meeting. 2008 Apr 27 - May 1; Fort Lauderdale, Florida, USA. Poster in PDF

Jacot JL, Jacot TA, Sheppard Jr. JD, Lattanzio Jr. FA, Williams PB, Brubaker K. Evaluation of MMP 2/9 modulation by azithromycin and DURASITE^® on human corneal epithelial cells and bovine corneal endothelial cells in vitro. Poster presented at the ARVO (Association for Research in Vision & Ophthalmology) 2008 Annual Meeting. 2008 Apr 27 - May 1; Fort Lauderdale, Florida, USA. Poster in PDF

Peterson WM, Lampe J, Navratil T, Paran Y, Kam Z, Hennes EA, Gabelt BT, Geiger B, Kaufman PL, Vittitow JL. Topical administration of a novel and potent rho kinase (ROK) inhibitor INS117548 alters the actin cytoskeleton, effectively lowers IOP, and is well tolerated on the ocular surface. Poster presented at the ARVO (Association for Research in Vision & Ophthalmology) 2008 Annual Meeting. 2008 Apr 27 - May 1; Fort Lauderdale, Florida, USA. Poster in PDF

Verhoeven RS, Kuney N, Robinson C, Peterson WM, Vittitow JL. Topical administration of cytoskeletal disrupting agents modulates central corneal thickness, pupil diameter and pupillary light response in the New Zealand white rabbit. Poster presented at the ARVO (Association for Research in Vision & Ophthalmology) 2008 Annual Meeting. 2008 Apr 27 - May 1; Fort Lauderdale, Florida, USA. Poster in PDF

deCamp JB, She J, Sharaf N, Watson PS. Efficient two-step protection of cysteine and its use in the synthesis of N-(p-methoxybenzyl)-4-acetyl-2-oxo-thiazolidinone. Poster presented at the Spring 2008 ACS (American Chemical Society) National Meeting. 2008 Apr 6-10; New Orleans, Louisiana, USA. Poster in PDF

Watson PS, Anderson SA, Douglass JG, Boyer JL, Crean CS, Mahanty S, Morgan AK, Verhoeven RS, and Samuelson CA. Inhibition of platelet aggregation via P2Y₁₂ receptor antagonists: Synthesis, SAR, chemical stability data, and biological results. Poster presented at the Spring 2008 ACS (American Chemical Society) National Meeting. 2008 Apr 6-10; New Orleans, Louisiana, USA. Poster in PDF

Crean C, Vittitow JL, Zink RC, Richards L, Verhoeven RS, Powell KD and Brazzell RK. Comparison of AZASITE^® and azithromycin 1% for bacterial conjunctivitis. PowerPoint presentation at the American Society of Cataract and Refractive Surgery (ASCRS) 2008 Annual Meeting. 2008 Apr 4-9; Chicago, Illinois, USA. Presentation in PDF

Kellerman D, Durham T, Schaberg A, Kuhn K, Woodring A, Brazzell K, Foulks G, Meltzer E. The use of oral antihistamines (OA) in moderate to severe dry eye patients. Poster presentated at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2008 Annual Meeting. 2008 Mar 14-18; Philadelphia, Pennsylvania, USA. Poster in PDF

Crean CS, Ratner P, Widmann M, Schaberg A, Kellerman D. Pharmacokinetic model of epinastine, an H₁ antagonist, after nasal administration. Poster presentated at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2008 Annual Meeting. 2008 Mar 14-18; Philadelphia, Pennsylvania, USA. Poster in PDF

Goss CH, McKone EF, Mathews D, Kerr D, Wanger JS, Millard SP, Cystic Fibrosis Therapeutics Development Network. Experience using centralized spirometry in the Phase 2 randomized, placebo-controlled, double-blind trial of denufosol in patients with mild to moderate cystic fibrosis. J Cyst Fibros. 2008 Mar; 7(2):147-153.

Douglass JG, Patel RI, Yerxa BR, Shaver SR, Watson PS, Bednarski K, Plourde R, Redick CC, Brubaker K, Jones AC, Boyer JL. Lipophilic modifications to dinucleoside polyphosphates and nucleotides that confer antagonist properties at the platelet P2Y₁₂ receptor. J Med Chem. 2008 Feb 28;51(4):1007-1025.

Farjo R, Peterson WM, Naash MI. Expression profiling after retinal detachment and reattachment: a possible role for aquaporin-0. Invest Ophthalmol Vis Sci. 2008 Feb;49(2):511-521.

Douglass JG, Decamp JB, Fulcher EH, Jones W, Mahanty S, Morgan A, Smirnov D, Boyer JL, Watson PS. Adenosine analogues as inhibitors of P2Y₁₂ receptor mediated platelet aggregation. Bioorg Med Chem Lett. 2008 Jan 13.

Kellerman D, Rossi Mospan A, Engels J, Schaberg A, Gorden J, Smiley L. Denufosol: A review of studies with inhaled P2Y₂ agonists that led to Phase 3. Pulm Pharmacol Ther. Epub 2007 December 31.

Ratner PH, Amar NJ, Hampel FC, van Bavel JH, Widmann MC, Kellerman D, Tian W, Schaberg A. Epinastine HCl nasal spray is effective and well tolerated for the treatment of seasonal allergic rhinitis. PowerPoint presentation at The 2007 Annual Meeting of American College of Allergy, Asthma, & Immunology (ACAAI). 2007 November 8-14; Dallas, Texas, USA. Abstract in PDF

LaVange L, Engels J, Accurso FJ. Analyzing percent change in cystic fibrosis clinical trials. Poster presented at The 21st Annual North American Cystic Fibrosis Conference (NACFC). 2007 October 3-6; Anaheim, California, USA. Poster in PDF

Mathews D, Schaberg A, Brandi V, Engels J, Gorden J, Deterding R. Pediatric experience from three integrated Phase 2 studies of denufosol tetrasodium inhalation solution. Poster presented at The 21st Annual North American Cystic Fibrosis Conference (NACFC). 2007 October 3-6; Anaheim, California, USA. Poster in PDF

Friedman JY, Hardy C, Dewitt EM, Schulman KA, Reed SD. Patterns of antibiotic use for patients with mild cystic fibrosis. Poster presented at The 21st Annual North American Cystic Fibrosis Conference (NACFC). 2007 October 3-6; Anaheim, California, USA. Poster in PDF

Thelin W, Lazarowski E, Boyer JL, Boucher R. Denufosol is a stable and potent inducer of airway secretion. Poster presented at The 21st Annual North American Cystic Fibrosis Conference. 2007 October 3-6; Anaheim, California, USA. Poster in PDF

Johnson FL, Boyer JL, Leese PT, Crean C, Krishnamoorthy R, Durham T, Fox AW, Kellerman DJ. Rapid and reversible modulation of platelet function in man by a novel P2Y₁₂ ADP-receptor antagonist, INS50589. Platelets. 2007 August;18(5):346-356.

Deterding RR, Lavange LM, Engels JM, Mathews DW, Coquillette SJ, Brody AS, Millard SP, Ramsey BW; for the Cystic Fibrosis Therapeutics Development Network and the Inspire 08-103 Working Group. Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis. Am J Respir Crit Care Med. 2007 August 15;176(4):362-369.

Watson PS, She J, Lampe JW, Polianski AB. The total systhesis of latrunculin B. Poster presented at The Gordon Research Confrence on Natural Products. 2007 July 22-27; Tilton, New Hampsire, USA.

Nichols K, Morris S, Tian W. An evaluation of the effects of epinastine HCl ophthalmic solution, 0.05% (ELESTAT^®) on contact lens comfort in subjects with contact lens intolerance during allergy season. Poster presented at the 110th Annual American Optometric Association (AOA) Congress Optometry's Meeting. 2007 June 27-July 1; Boston, Massachusetts, USA.

Kellerman D, Warren S, Rossi A, Taylor G, Smiley L. Deposition and pharmacokinetic studies with inhaled P2Y₂ agonists - Evidence of high lung delivery and minimal systemic exposure. Poster presented at the 30^th European Cystic Fibrosis Society (ECFS) Conference. 2007 June 13-16; Belek, Turkey. Poster in PDF

Rossi A, Brandi V, Engels J, Gorden J, Schaberg A, Smiley L. Reactive airway disease and cystic fibrosis: A retrospective analysis of the safety and tolerability with denufosol inhalation solution. Poster presented at the 30^th European Cystic Fibrosis Society (ECFS) Conference. 2007 June 13-16; Belek, Turkey. Poster in PDF

Wolff SC, Brubaker K, Navratil T, Fulcher EH, Lankford JR, Boyer JL. Evaluation of muscarinic receptor antagonism by antihistamines. Poster presented at the XXVI European Academy of Allergology and Clinical Immunology (EAACI) Congress. 2007 June 9-13; GÖteborg, Sweden. Poster in PDF

Lukat K-F, Kuna P, Sanquer F, Ivan P, Dimitrov V, Molina Gorina M, Van De Heyning PH, Loureiro AC, the Bilastine International Working Group, Valiente R, Sologuren A. Treatment with Bilastine improves symptoms in patients with seasonal allergic rhinitis. Poster presented at the XXVI European Academy of Allergology and Clinical Immunology (EAACI) Congress. 2007 June 9-13; GÖteborg, Sweden. Poster in PDF

Kuna P, Nowacki Z, Van Cauwenberghe P, Lukat KF, Spicakova M, Agache I, Fouquert L, Roger A, the Bilastine International Working Group, Sologuren A, Valiente R. A Phase 3 study comparing the efficacy and safety of once daily Bilastine with cetirizine and placebo for the treatment of Seasonal Allergic Rhinitis (SAR). Poster presented at the XXVI European Academy of Allergology and Clinical Immunology (EAACI) Congress. 2007 June 9-13; GÖteborg, Sweden. Poster in PDF

Brazzell R, Kellerman DJ, Schaberg A, Yerxa B,Durham T. Effect of diquafosol on ocular surface health in dry eye disease. Poster presented at The Association for Research in Vision and Ophthalmology (ARVO) 2007 Annual Meeting. 2007 May 6-10; Fort Lauderdale, Florida, USA. Poster in PDF

Ousler GW III, Brazzell K, Durham T, Walker P, Anderson RT, Abelson MB. A correlation between central corneal staining and visual function in patients diagnosed with dry eye. Poster presented at The Association for Research in Vision and Ophthalmology (ARVO) 2007 Annual Meeting. 2007 May 6-10; Fort Lauderdale, Florida, USA. Poster in PDF

Wolff SC, Brubaker K, Wright RC, Boyer JL. The pharmacological properties of epinastine on histamine H₂ and H₄ receptors. Poster presented at The Association for Research in Vision and Ophthalmology (ARVO) 2007 Annual Meeting. 2007 May 6-10; Fort Lauderdale, Florida, USA.

Bowman LM, Si E, Pang J, Friedlaender M. Development of a commercial eye drop formulation of azithromycin. Poster presented at The Association for Research in Vision and Ophthalmology (ARVO) 2007 Annual Meeting. 2007 May 6-10; Fort Lauderdale, Florida, USA. Poster in PDF

Yates KA, Romanowski EG, Kowalski RP, Mah FS, Gordon YJ. Frequent dosing with topical 1% azithromycin is effective in reducing azithromycin-resistant pseudomonas aeruginosa colony counts in a NZW rabbit model. Poster presented at The Association for Research in Vision and Ophthalmology (ARVO) 2007 Annual Meeting. 2007 May 6-10; Fort Lauderdale, Florida, USA. Poster in PDF

Cowlen M, Crean C, Poulin D, Ching S, Peterson W, Anderson S. 52-Week inhalation toxicology study of nebulized denufosol tetrasodium in Beagle dogs. Poster presented at the Society of Toxicology (SOT) 46th Annual Meeting. 2007 March 25-29; Charlotte, North Carolina, USA. Poster in PDF

Anderson S, Crean C, Poulin D, Ching S, Peterson W, Cowlen M. 26-Week inhalation toxicology study of nebulized denufosol tetrasodium in Sprague Dawley rats. Poster presented at the Society of Toxicology (SOT) 46th Annual Meeting. 2007 March 25-29; Charlotte, North Carolina, USA. Poster in PDF

Wolff SC, Brubaker K, Navratil T, Fulcher EH, Lankford JR and Boyer JL. Anticholinergic effects of antihistamine drugs used in the clinic. PowerPoint presentation at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2007 Annual Meeting. 2007 February 23-27; San Diego, California, USA. Presentation in PDF

Wolff SC, Brubaker K, Navratil T, Fulcher EH, Lankford JR and Boyer JL. Muscarinic receptor antagonism by marketed oral and topically applied antihistamines. Poster presented at the American Academy of Optometry (AAO) 2006 Annual Meeting. 2006 December 7-10; Denver, Colorado, USA. Poster in PDF

Brubaker K, Wright RC, Boyer JL. Persistent and insurmountable inhibition of the histamine H₁ receptor activity by epinastine. Poster presented at the 2006 American College of Allergy, Asthma & Immunology (ACAAI). 2006 November 9-15; Philadelphia, Pennsylvania, USA.

Deterding R, Milla C, Barnes M, Engels J, Koenig J, Williams C, Gorden J, Mathews D, Smiley L. Safety and tolerability of denufosol inhalation solution: results of a 28-day Phase 2 study in 5-7 year old patients with CF. Poster presented at the 2006 North American Cystic Fibrosis Conference. (NACFC) 2006 November 2-5; Denver, Colorado, USA. Poster in PDF

Yerxa BJ, Brazzell RK, Kellerman DJ, Schaberg AE, Durham TA. Mechanism and Clinical Overview of Diquafosol Tetrasodium, a P2Y₂ Agonist, For Dry Eye Disease. Powerpoint presentation by Dr. RK Brazzell at the XVII International Congress of Eye Research. 2006 October 29-November 3; Buenos Aires, Argentina. Abstract in PDF

Ezzell JA, Hansen MR, Anderson SA, Peterson WM, Eckert WA. Brief corneal inflammation produces delayed hyperalgesia and trigeminal dorsal horn sensitization. Poster presented at the Society for Neuroscience Annual Meeting - Neuroscience 2006. 2006 October 14-18; Atlanta, Georgia, USA. Poster in PDF

Mega B, Crean CS, Bode AP, Nifong LW, Sun YS, K Salleng, Chitwood R, Boyer JL. A reversible ADP platelet receptor antagonist maintains graft patency and preserves platelet function after cardiopulmonary bypass and CABG in a canine model. Poster presented at the Society for the Advancement of Blood Management Annual Meeting. 2006 September 15-17; Jersey City, New Jersey, USA.

Abbracchio MP, Burnstock G, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Knight GE, Fumagalli M, Gachet C, Jacobson KA, Weisman GA. International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol Rev. 2006 September; 58(3):281-341.

Smiley L, Rossi A, Mathews D, Engels J, Schaberg A, Kellerman D, Shaffer C, Deterding R. Denufosol tetrasodium inhalation solution: results from two Phase 2 trials in CF patients with mild to moderate lung disease. Powerpoint presentation by Dr. Lynn Smiley and Poster presented at the 29th European Cystic Fibrosis Conference. (ECFC) 2006 June 15-18; Copenhagen, Denmark. Presentation in PDF Poster in PDF

Crean CS, Boyer JL. The disposition, metabolism and elimination of INS50589, a potent, selective and reversible P2Y₁₂ receptor antagonist in rats. Poster presented at the 9th European International Society for the Study of Xenobiotics (ISSX) Meeting. 2006 June 4-7; Manchester, UK. Poster in PDF

Brubaker K, Yerxa BR, Boyer JL. In Vitro analysis of the antagonism of the histamine H₁ receptor by epinastine: A kinetic comparison with other marketed compounds. Poster presented at The Association for Research in Vision and Ophthalmology (ARVO) 2006 Annual Meeting. 2006 April 30 - May 4; Fort Lauderdale, Florida, USA. Poster in PDF

Eckert WA, Ezzell JA, Durham T, Lan L, Metzler AD, Hansen MR, Crean CS, Vittitow J, Peterson WM, Anderson SA. A novel objective assay for evaluating rodent behavioral responses associated with corneal irritation and injury. Poster presented at The Association for Research in Vision and Ophthalmology (ARVO) 2006 Annual Meeting. 2006 April 30 - May 4; Fort Lauderdale, Florida, USA. Poster in PDF

Ezzell JA, Peterson WM, Crean CS, Vittitow JL. Ocular Pharmacokinetics in aqueous and vitreous humor of a single intravitreal injection of denufosol tetrasodium (INS37217) in Dutch belted rabbits. Poster presented at The Association for Research in Vision and Ophthalmology (ARVO) 2006 Annual Meeting. 2006 April 30 - May 4; Fort Lauderdale, Florida, USA. Poster in PDF

Nichols KK, King-Smith PE, Nichols JJ, and Kellerman D. Tear film thickness and thinning rate following a six-week trial of 2% diquafosol tetrasodium vs. placebo in dry eye patients. Poster presented at The Association for Research in Vision and Ophthalmology (ARVO) 2006 Annual Meeting. 2006 April 30 - May 4; Fort Lauderdale, Florida, USA. Poster in PDF

Ousler III GW, Kellerman D, Durham T, Brazzell K, Kennedy K, Abelson MB. An association between central corneal staining and dry eye symptomatology. Poster presented at The Association for Research in Vision and Ophthalmology (ARVO) 2006 Annual Meeting. 2006 April 30 - May 4; Fort Lauderdale, Florida, USA. Poster in PDF

Vittitow JL, Eckert WA, Ezzell JA, Verhoeven RS, Peterson WM, Anderson SA. An experimental model of chronic dry eye combining extraorbital lacrimal gland excision and subcutaneous scopolamine in the rat. Poster presented at The Association for Research in Vision and Ophthalmology (ARVO) 2006 Annual Meeting. 2006 April 30 - May 4; Fort Lauderdale, Florida, USA. Poster in PDF

Bourdon DM, Mahanty SK, Jacobson KA, Boyer JL, Harden TK. (N)-methanocarba-2MeSADP (MRS2365) is a subtype-specific agonist that induces rapid desensitization of the P2Y₁ receptor of human platelets. J Thromb Haemost. 2006 April;4(4):861-868.

Johnson FL, Boyer JL, Leese PT, Durham T, Crean CS, Krishnamoorthy R, Kellerman DJ. Pharmacological evaluation of a novel, rapidly reversible intravenous platelet P2Y₁₂ ADP receptor antagonist, INS50589 in healthy volunteers. J Am Coll Cardiol. 2006; 47(4 Suppl B): 51.

Johnson FL, Boyer JL, Leese PT, Durham T, Crean CS, Krishnamoorthy R, Kellerman DJ. Pharmacological evaluation of a novel, rapidly reversible intravenous platelet P2Y₁₂ ADP receptor antagonist, INS50589 in healthy volunteers. Poster presented at the American College of Cardiology (AAC) 55th Annual Meeting. 2006 March 11-14; Atlanta, Georgia, USA. Poster in PDF

Crean CS, Bode AP, Sun Y-S, Nifong W, Cowlen M, Anderson S, Peterson W, Boyer JL. Antiplatelet treatment with P2Y₁₂ receptor antagonist decreases blood loss in a canine CABG model with cardiopulmonary bypass. J Am Coll Cardiol 2006; 47(4 Suppl A): 191A.

Crean CS, Bode AP, Sun Y-S, Nifong W, Cowlen M, Anderson S, Peterson W, Boyer JL. Antiplatelet treatment with P2Y₁₂ receptor antagonist decreases blood loss in a canine CABG model with cardiopulmonary bypass. Poster presented at the American College of Cardiology (AAC) 55th Annual Meeting. 2006 March 11-14; Atlanta, Georgia, USA. Poster in PDF

Cowlen M, Crean C, Krishnamoorthy R, Richards L, Watson P, Boyer JL. Cardiopulmonary safety and toxicology evaluation of INS50589, a reversible P2Y₁₂ receptor antagonist with anti-platelet aggregation activity, administered by continuous intravenous infusion in beagle dogs. Poster presented at the Society of Toxicology Annual Meeting; 2006 March 5-9; San Diego, California, USA.

Johnson FL, Boyer J, Crean CS, Durham T, Krishnamoorthy R, Kellerman DJ. Phase 1 pharmacokinetic, pharmacodynamic, and safety evaluation of a novel rapidly reversible intravenous platelet P2Y₁₂ ADP receptor antagonist, INS50589. J Thromb Haemost 2005; 3 (Suppl 1): P2206.

Bode AP, Crean CS, Sun YS, Nifong W, Cowlen M, Anderson S, Peterson W, Boyer JL. Effect of INS50589, a reversible ADP-receptor antagonist, on platelet function and blood loss in a canine model of cardiopulmonary bypass. Poster presented at the American Society of Hematology 47th Annual Meeting. 2005 December 10-13; Atlanta, Georgia, USA.

Evans R, Bogden ME, Tservistas M, Braun A, Seeman S, Keller M. Comparison of the rates of drug delivery and the relative efficiencies of emitted and respirable dose for two different nebulizers yielding qualitatively similar aerosols. Poster presented at the Drug Delivery to the Lungs 16 Meeting. 2005 December 7-9; Edinburgh, Scotland.

Kellerman DJ, Chia VW, Ice JC. Comprehensive review of the in vivo ocular tolerability and safety of ELESTAT^® (epinastine ophthalmic solution, 0.05%). Poster presented at the 2005 American College of Allergy, Asthma & Immunology (ACAAI) Annual Meeting. 2005 November 4-9; Anaheim, California, USA.

Evans R, Ellis Bogden M, Tservistas M, Seeman S, Keller M. Optimization of aerosol characteristics of the eFLOW^® electronic nebulizer for pulmonary delivery of a P2Y₂ agonist. Poster presented at the 19th Annual North American Cystic Fibrosis Conference. (NACFC) 2005 October 20-23; Baltimore, Maryland, USA. Poster in PDF

Douglass JG, Patel RI, Cowlen MC, Yerxa BR, Shaver SR, Crean CS, Peterson WM, Watson PS, Bednarski K, Plourde R Jr., Mahanty S, Boyer JL. INS50589, a potent, selective, and reversible inhibitor of P2Y₁₂-mediated platelet aggregation. PowerPoint presentation at the 230^th American Chemical Society National Meeting and Exposition. 2005 August 28 - September 1; Washington, DC, USA.

Johnson FL, Boyer JL, Crean CS, Durham T, Krishnamoorthy R, Watson PS, Kellerman DJ. Phase 1 pharmacokinetic, pharmacodynamic, and safety evaluation of a novel rapidly reversible intravenous platelet P2Y₁₂ ADP receptor antagonist, INS50589. Poster presented at The International Society on Thrombosis & Haemostasis XXth Congress and 51st Annual SSC Meeting. 2005 August 6-12; Sydney, Australia.

Mathews D, Schaberg A, Kellerman D, LaVange L, Engels J, Shaffer C. INS37217 (denufosol tetrasodium) inhalation solution: Phase 1 & 2 clinical experience. Presentation and poster presented at the 28th European Cystic Fibrosis Conference. (ECFC) 2005 June 23-25; Crete, Greece. Poster in PDF

LaVange L,Engels J, Knowles M, Deterding R, Mathews D, Shaffer C. Safety and efficacy of INS37217 inhalation solution in patient subgroups: Results of a Phase 2 multicentre trial. Presentation and poster presented at the 28th European Cystic Fibrosis Conference. (ECFC) 2005 June 23-25; Crete, Greece. Poster in PDF

LaVange LM, Durham TA, Koch GG. Randomization-based nonparametric methods for the analysis of multicentre trials. Stat Methods Med Res. 2005 Jun;14(3): 281-301.

Schaberg AE, Durham TA, Kuhn KL, Caspar RA, LaVange LM. An evaluation of worst symptom reporting in a dry eye clinical trial. Poster presented at The Association for Research in Vision and Ophthalmology (ARVO) 2005 Annual Meeting. 2005 May 1-5; Fort Lauderdale, Florida, USA.

Shaver SR, Rideout JL, Pendergast W, Douglass JG, Brown EG, Boyer JL, Patel RI, Redick CC, Jones AC, Picher M, Yerxa BR. Structure-activity relationships of dinucleotides: Potent and selective agonists of P2Y receptors. Purinergic Signalling. 2005; 1:183-191.

Deterding R, Retsch-Bogart G, Milgram L, Gibson R, Daines C, Zeitlin PL, Milla C, Marshall B, Lavange L, Engels J, Mathews D, Gorden J, Schaberg A, Williams J, Ramsey B. Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y₂ receptor agonist: Results of a Phase 1/Phase 2 multicenter study in mild to moderate cystic fibrosis. Pediatr Pulmonol. 2005 Apr;39(4):339-348.

Cowlen M, Crean C, Krishnamoorthy R, Watson PS, Boyer JL, Peterson WM, Anderson SA. Pharmacology and tolerability of INS50589, a reversible P2Y₁₂ receptor antagonist with anti-platelet aggregation activity, administered by continuous intravenous infusion in rats and dogs. Poster presentation at the Society of Toxicology 44th Annual Meeting. 2005 March 6-10; New Orleans, Louisiana, USA.

Tauber J, Davitt WF, Bokosky JE, Nichols KK, Yerxa BR, Schaberg AE, LaVange LM, Mills-Wilson MC, Kellerman DJ. Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye. Cornea, 2004 Nov;23(8):784-792.

Schaberg A, Ousler G, Kellerman D, LaVange L, Durham T, Yerxa B. Diquafosol tetrasodium (INS365) treatment and corneal clearing: Evidence from clinical trials. Poster presentation at the 4th Annual International Conference on the Lacrimal Gland, Tear Film, Ocular Surface and Dry Eye Syndromes. 2004 November 17-20; Fajardo, Puerto Rico.

Durham TA, LaVange LM, Kellerman DJ, Schaberg AE. Improvement in subject's worst symptom associated with treatment of 2.0% diquafosol tetrasodium in two studies of dry eye disease. Poster presentation at the 4th Annual International Conference on the Lacrimal Gland, Tear Film, Ocular Surface and Dry Eye Syndromes. 2004 November 17-20; Fajardo, Puerto Rico.

Smirnov D and Watson PS. Adenine nucleosides with N6-urea modifications as inhibitors of P2Y₁₂ mediated platelet aggregation. Poster presentation at the 2004 Southeastern Regional Meeting of the American Chemical Society (SERMACS). 2004 November 13; Research Triangle Park, North Carolina, USA.

Glaub E and Douglass J. Adenine nucleosides with 5'-sulfide and sulfone modifications as inhibitors of P2Y₁₂ mediated platelet aggregation. Poster presentation at the 2004 Southeastern Regional Meeting of the American Chemical Society (SERMACS). 2004 November 13; Research Triangle Park, North Carolina, USA.

deCamp JB and Plourde R Jr. Adenosine nucleosides with 5'-amino and amido modifications as inhibitors of P2Y₁₂ mediated platelet aggregation. Poster presentation at the 2004 Southeastern Regional Meeting of the American Chemical Society (SERMACS). 2004 November 13; Research Triangle Park, North Carolina, USA.

Monson BK, Rothman JS, Raizman MB. Efficacy and tolerability of ophthalmic epinastine for treatment of seasonal allergic conjunctivitis: A randomized, double-masked, active-controlled clinical trial. Poster presentation at the 2004 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI). 2004 November 12-17; Boston, Massachusetts, USA.

Brazzell RK, Vix J-M, Boshoff L. Efficacy of ophthalmic epinastine for treatment of signs and symptoms of allergic conjunctivitis in cat-sensitive subjects. Poster presentation at the 2004 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI). 2004 November 12-17; Boston, Massachusetts, USA.

Crean CS, Ekdert WA III, Howard JL, Polard GT, Boncek MV, Lan L, Durham T, Peterson WM. Nociceptive activity/agitation behavioral response in rats: A novel objective assay. Poster presentation at the Neuroscience 2004 34^th Annual Meeting. 2004 October 23-27; San Diego, California, USA.

Kellerman DJ, Mills-Wilson M, Johnson C. Pharmacokinetics of INS37217 after inhaled and intravenous administration in healthy volunteers. Poster presentation at the 2004 North American Cystic Fibrosis Conference. 2004 October 14-17; St. Louis, Missouri, USA. Poster in PDF

Goss CH, Mathews D, Kerr D, Wanger JS, Millard SP. Experience using centralized spirometry in the Phase 2 randomized placebo controlled double blind trial of INS37217 inhalation solution in patients with mild CF. Powerpoint and poster presentation at the 2004 North American Cystic Fibrosis Conference. 2004 October 14-17; St. Louis, Missouri, USA. Poster in PDF

Brody AS, Robinson TE, Knowles MR, Goris ML, LaVange LM, Engels JM. High resolution CT in an intervention study in cystic fibrosis. Powerpoint and poster presentation at the 2004 North American Cystic Fibrosis Conference. 2004 October 14-17; St. Louis, Missouri, USA. Poster in PDF

Deterding R, LaVange L, Mathews D, Engels J, Gorden J, Shaffer C, Coquillette S, Ramsey B. Safety and efficacy of INS37217 inhalation solution, a novel P2Y₂ receptor agonist, in patients with mild cystic fibrosis: Results of a Phase 2 multi-center study. Powerpoint and poster presentation at the 2004 North American Cystic Fibrosis Conference. (NACFC) 2004 October 14-17; St. Louis, Missouri, USA. Poster in PDF

Boyer JL, Patel RI, Douglass JG, Cowlen M, Crean CS, Whitsell R, Peterson, W, Shaver SR, Watson PS, Krishnamoorthy R, Hechler B, Gachet C, Yerxa BR. Development of reversible P2Y₁₂ receptor antagonists. Powerpoint presentation at the 3rd International Meeting, ADP 2004, P2 Receptors and Other, New Targets for Antithrombotic Drugs. 2004 September 16-18; Lucca, Tuscany, Italy. Abstract in PDF

Douglass JG, Bednarski K, Crean CS, Shaver SR. Effects of ribose modified adenosine phosphates in models of acute and inflammatory pain. Poster presented at the 4th International Symposium of Nucleosides and Nucleotides Purines 2004 Meeting. 2004 June 6-9; Chapel Hill, North Carolina, USA. Poster in PDF

Douglass JG, Patel RI, Redick CC, Jones AC, Shaver SR, Boyer JL. Lipophilic adenine nucleotides as reversible inhibitors of P2Y₁₂-mediated platelet aggregation. Poster presented at the 4th International Symposium of Nucleosides and Nucleotides Purines 2004 Meeting. 2004 June 6-9; Chapel Hill, North Carolina, USA. Poster in PDF

Patel RI, Douglass JG, Cowlen M, Crean CS, Whitsell R, Peterson W, Shaver SR, Watson PS, Krishnamoorthy R, Gachet C, Hechler B, Yerxa BR, Boyer JL. In vivo antiplatelet activity of a reversible P2Y₁₂ receptor antagonist. Poster presented at the 4th International Symposium of Nucleosides and Nucleotides Purines 2004 Meeting. 2004 June 6-9; Chapel Hill, North Carolina, USA.

Johnson FL, Turic B, Kemp R, Palcic B, Sussman R, Voelker KG, Robinette E. Improved diagnostic sensitivity for lung cancer using an automated quantitative cytology system and uridine 5'-triphosphate-induced sputum specimens. Chest. 2004 May;125 (5 Suppl): 157S-158S.

Barber LD, Durham T, LaVange L, Kellerman D, Schaberg A, Sall K, Nichols K, Yerxa B. Effect of diquafosol on worst symptom of dry eye patients: focus on photophobia. Poster presented at The Association for Research in Vision and Ophthalmology (ARVO) 2004 Annual Meeting. 2004 April 25-29; Fort Lauderdale, Florida, USA. Poster in PDF

Kellerman DJ, Ousler G, Abelson M, Welch D, Mayhew A, Durham T, LaVange L, Yerxa B. Placebo-controlled evaluation of diquafosol in a controlled adverse environment (CAE). Poster presented at The Association for Research in Vision and Ophthalmology (ARVO) 2004 Annual Meeting. 2004 April 25-29; Fort Lauderdale, Florida, USA.

Sheppard J, Alison N, Martin D, Durham T, LaVange L, Kellerman D, Yerxa B, Schaberg A. Diquafosol tetrasodium is effective in a broad spectrum of patients with dry eye. Poster presented at The Association for Research in Vision and Ophthalmology (ARVO) 2004 Annual Meeting. 2004 April 25-29; Fort Lauderdale, Florida, USA.

Farjo R, Nour M, Oulambao AB, Peterson W, Naash MI. Retinal transcriptome analysis during the resolution of retinal detachment accomplished by P2Y₂ receptor agonist INS37217. Poster presented at The Association for Research in Vision and Ophthalmology (ARVO) 2004 Annual Meeting. 2004 April 25-29; Fort Lauderdale, Florida, USA.

Peral A, Hakim N, Carracedo G, Fernández I, Yerxa B, Pintor J. Nucleotidic substances increase tear lysozyme levels in New Zealand white rabbits. Poster presented at The Association for Research in Vision and Ophthalmology (ARVO) 2004 Annual Meeting. 2004 April 25-29; Fort Lauderdale, Florida, USA.

Douglass JG, Patel RI, Redick C, Jones AC, Shaver SR, Boyer JL. Adenine mononucleotides modified with lipophilic acetal and urea moieties as reversible P2Y₁₂ receptor antagonists. Poster presented at the 227th Annual American Chemical Society (ACS) Meeting. 2004 March 28-April 1; Anaheim, California, USA.

Oloff S, Khashan R, Plourde R, Tropsha A. Computational based discovery of novel antiplatelet compounds. Poster presented at the 227th Annual American Chemical Society (ACS) Meeting. 2004 March 28-April 1; Anaheim, California, USA.

Winther B, Henry D, Schaberg AE, Kuhn KL, Keyes-Elstein L, Kellerman DJ, Hayden FG. INS37217 nasal spray, a P2Y₂ receptor agonist, as a novel treatment for common cold. Poster presented at American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting. 2004 March 19-23; San Francisco, California, USA.

Crean CS, Yerxa BR, Bednarski K, Peterson WM. Analgesic effects of INS48506, a P2X₃ receptor antagonist, in models of acute, inflammatory and neuropathic pain. Poster presented at Neuroscience 2003. 2003 November 8-12; New Orleans, Louisiana, USA.

Noone PG, Foy C, Shaffer C, Mathews D, Schaberg A, Boucher RC, Knowles MR. Dose effect for a novel P2Y₂ agonist INS37217 to induce Cl^- secretion across normal and CF airway epithelia. Poster presented at The Seventeenth Annual North American Cystic Fibrosis Conference. 2003 October 16-19; Anaheim, California, USA.

Foulks GN. Effects of diquafosol tetrasodium (a P2Y₂ receptor agonist) on ocular surface staining. Presentation at EVER (European Association for Vision and Eye Research) 2003 Annual Meeting. 2003 October 8-11; Alicante, Spain. Powerpoint presentation in PDF

Yerxa BR, Cowlen MC, Fischbarg J, Nakata K, Murakami T, Fujihara T, Nakamura M. Diquafosol tetrasodium: mechanism of action and clinical relevance. Poster presented at the 23rd Biennial Cornea Research Conference. 2003 October 3-4; Boston, Massachusetts, USA. Poster in PDF

Donshik P, Tauber J, Schaberg AE, Durham T, LaVange LM, Yerxa BR, Kellerman DJ. Diquafosol tetrasodium reduces corneal and conjunctival staining in subjects with dry eye, with the largest benefit relative to placebo observed in subjects with severe disease. Poster presented at the 23rd Biennial Cornea Research Conference. 2003 October 3-4; Boston, Massachusetts, USA. Poster in PDF

Johnson FL, Gill GW, Erozan YS, Frable WJ, Gupta PK. Improved diagnostic sensitivity for lung cancer from cell block sections plus cytospin and smear preparations of sputum specimens induced with INS316. Poster presented at The 10th World Conference on Lung Cancer. 2003 August 10-14; Vancouver, Canada.

Cowlen MS, Zhang VZ, Warnock L, Moyer CF, Peterson WM, Yerxa BR. Localization of ocular P2Y₂ receptor gene expression by in situ hybridization. Exp Eye Res. 2003 Jul;77(1):77-84.

Johnson FL, Turic B, Kemp R, Palcic B, Sussman R, Voelker KG, Robinett E, ZuWallack R, Morganroth M, Yung R, Simon S, Osmanski J. Improved diagnostic sensitivity for lung cancer using an automated quantitative cytology (AQC) system and UTP-induced sputum specimens. Poster presented at The Thomas L. Petty Aspen Lung Conference 46th Annual Meeting. 2003 June 4-7; Aspen, Colorado, USA.

Tauber J, Davitt WF, Bokosky JE, Nichols KK, Mills-Wilson MC, Schaberg AE, Yerxa BR, LaVange LM, Kenny SJ, Kellerman DJ. Double masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye. Poster presented at The Association for Research in Vision and Ophthalmology (ARVO) 2003 Annual Meeting. 2003 May 4-9; Fort Lauderdale, Florida, USA. Poster in PDF

Kellerman DJ, Sall KN, Bokosky JE, Mills-Wilson MC, Whitsell RS, Kaufman BD, Yerxa BR. Diquafosol tetrasodium (INS365) ophthalmic solution is not absorbed systemically in patients with dry eye. Poster presented at The Association for Research in Vision and Ophthalmology (ARVO) 2003 Annual Meeting. 2003 May 4-9; Fort Lauderdale, Florida, USA. Poster in PDF

Gomez LM, Siderovski DP, Peterson WM. Localization of regulator of G protein signaling 11 (RGS11) in rat and monkey photoreceptors and RPE. Poster presented at The Association for Research in Vision and Ophthalmology (ARVO) 2003 Annual Meeting. 2003 May 4-9; Fort Lauderdale, Florida, USA. Poster in PDF

Podos SM, Wang R-F, Boyer JL, Yerxa BR, Serle JB. Effect of the P2Y₁₄ receptor agonist, UDP-glucose, on intraocular pressure (IOP) in glaucomatous monkey eyes. Poster presented at The Association for Research in Vision and Ophthalmology (ARVO) 2003 Annual Meeting. 2003 May 4-9; Fort Lauderdale, Florida, USA. Poster in PDF

Tornambe PE, Fox GM, Poliner LS, King BJ, Whitsell RS, LaVange LM, Kellerman DJ, Peterson WM. A double-masked, randomized, placebo-controlled, dose-escalating study of a single intravitreal injection of INS37217 in subjects with retinal detachment. Powerpoint presentation at The Association for Research in Vision and Ophthalmology (ARVO) 2003 Annual Meeting. 2003 May 4-9; Fort Lauderdale, Florida, USA.

Serle JB, Wang R-F, Peterson WM, Plourde R, Yerxa BR, Podos SM. Effect of 5-MCA-NAT, a putative melatonin MT3 receptor agonist, on intraocular pressure (IOP) in glaucomatous monkey eyes. Powerpoint presentation at The Association for Research in Vision and Ophthalmology (ARVO) 2003 Annual Meeting. 2003 May 4-9; Fort Lauderdale, Florida, USA.

Jones AC, Patel RI, Douglass J, Redick C, Brubaker K, Shaver SR, Yerxa BR, Boyer JL. Adenosine 5' diphosphate analogues with ribose & base substitutions that confer P2Y₁₂ antagonist properties. Poster presented at Experimental Biology 2003. 2003 April 11-15; San Diego, California, USA.

Kaufman B, Novack GD. Compliance issues in manufacturing of drugs. Ocul Surf. 2003 Apr;1(2): 80-85.

Schaberg AE, Meltzer AO, LaForce CF, Pearlman DS, Ice JC, LaVange LM, Kellerman DJ. INS37217 intranasal, a P2Y₂ receptor agonist, is a novel treatment for allergic rhinitis. Poster presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) 60th Anniversary Meeting. 2003 March 7-12; Denver, Colorado, USA. Poster in PDF

Min K, Munarriz R, Yerxa BR, Goldstein I, Shaver SR, Cowlen MS, Traish AM. Selective P2Y₂ receptor agonists stimulate vaginal moisture in ovariectomized rabbits. Fertil Steril. 2003 Feb;79(2):393-8.

Kellerman D, Evans R, Mathews D, Shaffer C. Inhaled P2Y₂ receptor agonists as a treatment for patients with cystic fibrosis lung disease. Adv Drug Deliv Rev. 2002 Dec 5;54(11):1463-1474.

Johnson FL, Donohue JF, Shaffer CL. Improved sputum expectoration following a single dose of INS316 in patients with chronic bronchitis. Chest. 2002 Dec;122(6): 2021-2029.

Meltzer EO, Ice JC, LaVange LM, Kellerman DJ, Schaberg AE. INS37217, a P2Y₂ receptor agonist given intranasally, is well tolerated and decreases saccharin transport time in subjects with and without perennial allergic rhinitis. Results presented at the 2002 American College of Allergy, Asthma & Immunology Annual Meeting. 2002 November 15-20, San Antonio, Texas.

Douglass J, Patel RI, Redick C, Brubaker K, Jones AC, Shaver SR, Yerxa B, Baurand A, Gachet C, Boyer JL. Ribose and nucleobase modifications to nucleotides that confer antagonist properties against the platelet P2Y₁₂ receptor. Poster presented at The Platelet ADP Receptors 2nd International Meeting. 2002 October 3-5; Sardinia, Italy.

Deterding R, Engels J, Shaffer C, Kellerman D, Mathews D, LaVange L, Gorden J, Quittner A, Williams J, Ramsey B. Safety and tolerability of INS37217 inhalation solution, a novel P2Y₂ receptor agonist, in patients with mild to moderate cystic fibrosis: Results of a Phase 1/2 multi-center study. Poster presented at the 2002 North American Cystic Fibrosis Conference. (NACFC) 2002 October 3-6; New Orleans, Louisiana, USA. Poster in PDF

Deterding R, Engels J, Shaffer C, Kellerman D, Mathews D, LaVange L, Gorden J, Quittner A, Williams J, Ramsey B. Safety and tolerability of INS37217 inhalation solution, a novel P2Y₂ receptor agonist, in patients with mild to moderate cystic fibrosis: Results of a Phase 1/2 multi-center study. Powerpoint presentation by Robin Deterding, MD at the 2002 North American Cystic Fibrosis Conference. (NACFC) 2002 October 3-6; New Orleans, Louisiana, USA.

Yerxa BR, Sabater JR, Davis CW, Stutts MJ, Lang-Furr M, Picher M, Jones AC, Cowlen M, Dougherty R, Boyer J, Abraham WM, Boucher RC. Pharmacology of INS37217 [P¹-(uridine 5')-P⁴-(2'-deoxycytidine 5')tetraphosphate, Tetrasodium Salt], a next-generation P2Y₂ receptor agonist for the treatment of cystic fibrosis. J Pharmacol Exp Ther, 2002 Sep, 302(3):871-880.

Plourde R Jr., Brown EG, Pelaez T, Peral A, Peterson W, Yerxa B, Pintor J. Design of novel melatonin analogs for reduction of intraocular pressure. Poster presented at IUPHAR 2002 - XIVth World Congress of Pharmacology. 2002 July 7-12; San Francisco, California, USA.

Jones AC, Redick CC, Zhang V, Brubaker K, Patel RI, Boyer JL. Characterization of 2MeSADP response in wild type 1321N1 human astrocytoma cells. Poster presented at IUPHAR 2002 - XIVth World Congress of Pharmacology. 2002 July 7-12; San Francisco, California, USA.

Patel RI, Douglass J, Redick C, Brubaker K, Jones AC, Shaver SR, Yerxa B, Boyer JL. Identification of a ribose substitution that confers antagonist properties to ADP against the platelet P2Y₁₂ receptor. Poster presented at IUPHAR 2002 - XIVth World Congress of Pharmacology. 2002 July 7-12; San Francisco, California, USA.

Cowlen MS, Bazemore EK, Gomez LM, Yerxa B, Peterson WM, Stutts MJ. P2Y₂ receptor gene expression and regulation of short circuit current (Isc) by P2Y₂ receptor agonists in endocervical epithelial cells. Poster presented at IUPHAR 2002 - XIVth World Congress of Pharmacology. 2002 July 7-12; San Francisco, California, USA.

Zhang VZ, Yerxa BR, Cowlen MS. Cellular distribution of P2Y₂ receptor gene expression in the primate gastrointestinal tract by in situ hybridization. Poster presented at IUPHAR 2002 - XIVth World Congress of Pharmacology. 2002 July 7-12; San Francisco, California, USA.

Brubaker KE, Redick C, Patel R, Jones A, Boyer JL. High throughput screening for agonists and antagonists of ADP receptors. Poster presented at IUPHAR 2002 - XIVth World Congress of Pharmacology. 2002 July 7-12; San Francisco, California, USA.

Douglass J, Yerxa B, Boyer JL, Redick C, Patel R, Jones A. Dinucleoside tetraphosphates modified with lipophilic substituents on the ribose hydroxyls: selected structure-activity relationships at nucleotide G-protein coupled receptors. Poster presented at IUPHAR 2002 - XIVth World Congress of Pharmacology. 2002 July 7-12; San Francisco, California, USA.

Boyer JL, Patel RI, Redick C, Brubaker K, Douglass J, Shaver S, Baurand A, Gachet C, Yerxa B. Inhibition of platelet aggregation by novel selective P2Y₁₂ receptor antagonists. Poster presented at IUPHAR 2002 - XIVth World Congress of Pharmacology. 2002 July 7-12; San Francisco, California, USA.

Baurand A, Patel RI, Redick K, Douglass J, Shaver S, Yerxa B, Boyer JL, Cazenave JP, Gachet C. Reduced thromboembolism in mice treated with a novel class of P2Y₁₂ receptor antagonists. Poster presented at IUPHAR 2002 - XIVth World Congress of Pharmacology. 2002 July 7-12; San Francisco, California, USA.

Crean C, Douglass J, Yerxa B, Redick K, Patel R, Jones A. Dinucleoside tetraphosphates with base lipophilic substituent modifications: selected structure-activity relationships at nucleotide G-protein coupled receptors. Poster presented at IUPHAR 2002 - XIVth World Congress of Pharmacology. 2002 July 7-12; San Francisco, California, USA.

Gomez L, Venturini AE, Peterson WM. Profiling the activation of many intracellular signaling proteins in response to stimulation of P2Y₂ receptors using a high-output western blot assay. Poster presented at IUPHAR 2002 - XIVth World Congress of Pharmacology. 2002 July 7-12; San Francisco, California, USA.

Brown EG, Boyer J, Shaver SR. Detection of INS316, INS365 and other nucleotides in plasma and fluids by LC/MS. Poster presented at IUPHAR 2002 - XIVth World Congress of Pharmacology. 2002 July 7-12; San Francisco, California, USA.

Bednarski K, Douglass JG, Redick CC, Jones AC, Patel RI, Shaver SR. Modified nucleoside polyphosphates as platelet aggregation. Poster presented at IUPHAR 2002 - XIVth World Congress of Pharmacology. 2002 July 7-12; San Francisco, California, USA.

Shaver SR, Douglass JG, Brown EG, Patel RI, Redick CC, Jones AC, Boyer JL, Picher M, Yerxa BR. P2Y receptor agonists: a comparison of mixed-base dinucleotides versus same-base dinucleotides and their deoxyribo-analogues. Poster presented at IUPHAR 2002 - XIVth World Congress of Pharmacology. 2002 July 7-12; San Francisco, California, USA.

Johnson FL, Yung RC-W, Sussman R, ZuWallack RL, Kellerman DJ. Improved lung cancer diagnostic value of sputum induced with a single inhaled dose of INS316 (uridine 5'-triphosphate). Poster presented at the American Thoracic Society (ATS) 98th International Conference. 2002 May 17-22; Atlanta, Georgia, USA.

Peral A, Bautista A, Carracedo G, Yerxa BR, Pintor J. Nucleotides and dinucleotides increase re-epithelialisation in rabbit corneal wounds. Poster presented at The Association for Research in Vision and Ophthalmology (ARVO) 2002 Annual Meeting. 2002 May 5-10; Fort Lauderdale, Florida, USA.

Wen Q, Li Y, Kuang K, Zuniga FA, Iserovich P, Yerxa B, Fischbarg J. Effects of P2Y₂ agonists on lipid secretion by cultured rabbit meibocytes. Poster presented at The Association for Research in Vision and Ophthalmology (ARVO) 2002 Annual Meeting. 2002 May 5-10; Fort Lauderdale, Florida, USA.

Donshik PC, Sall KN, Cacioppo LR, Whitsell RN, Mayhew AL, Yerxa BR, Crockett RS, Kellerman DJ. Presenting symptoms from diary cards for dry eye clinical trial subjects. Poster presented at The Association for Research in Vision and Ophthalmology (ARVO) 2002 Annual Meeting. 2002 May 5-10; Fort Lauderdale, Florida, USA.

Kellerman DJ. P2Y₂ receptor agonists: a new class of medication targeted at improved mucociliary clearance. Chest. 2002 May;121 (5 Suppl): 201S-205S.

Redick CC, Jones AC, Zhang V, Brubaker K, Patel RI, Boyer JL. Endogenous expression of P2Y₁ receptors in 1321N1 human astrocytoma cells. Poster presented at the Federation of American Societies for Experimental Biology Annual Meeting. 2002 April 20-24; New Orleans, Louisiana, USA.

Pintor J, Peral A, Hoyle C, Redick C, Douglass J, Yerxa B. Effects of diadenosine polyphosphates on tear secretion in New Zealand white rabbits. J Pharmacol Exp Ther, 2002 Jan, 300(1):291-297.

Pendergast W and Evans R. P2Y Receptor Agonists: Role in Mucosal Hydration and Mucociliary Clearance. New Drugs for Asthma, Allergy and COPD, 2002, 31(5):165-168.

Yerxa BR, Mundasad M, Sylvester RN, Garden JC, Cooper M, Kellerman DJ. Ocular safety of INS365 ophthalmic solution, a P2Y₂ agonist, in patients with mild to moderate dry eye disease. Adv Exp Med Biol. 2002; 506(Pt B): 1251-1257.

Yerxa BR. Industry perspective. Adv Exp Med Biol. 2002;506 (Pt B):1343-1344.

Yerxa BR, Douglass JG, Elena PP, Caillaud T, Amar T, Edick C, Peterson WM. Potency and duration of action of synthetic P2Y₂ receptor agonists on Schirmer scores in rabbits. Adv Exp Med Biol. 2002;506 (Pt A): 261-265.

Novack GD, Evans R. Commercially available ocular hypotensive products: preservative concentration, stability, storage and in-life utilization. J Glaucoma, 2001 Dec, 10:483-486.

Yerxa B, Zhang L, Sheridan C, Peterson W, Cowlen M. Cellular expression of P2Y₂ receptor mRNA as visualized by in situ hybridization in rabbit and monkey eyes. Poster presented at the European Association for Vision and Eye Research. 2001 October 10-13; Alicante, Spain.

Jablons DM, Everett D, David G, Michels RY, Klein MG, Edgar P, Johnson FL. A single inhaled dose of INS316 (uridine 5'-triphosphate, UTP) enhances sputum quality for the diagnosis of lung cancer. Poster presented at the 11th Annual Meeting of the European Respiratory Society. 2001 September 22-26; Berlin, Germany.

Shaver SR. P2Y receptors: Biological advances and therapeutic opportunities. Curr Opin Drug Discov Devel, 2001 Sep, 4(5):665-670.

Noone PG, Hamblett N, Accurso F, Aitken ML, Boyle M, Dovey M, Gibson R, Johnson C, Kellerman D, Konstan MW, Milgram L, Mundahl J, Retsch-Bogort G, Rodman D, Williams-Warren J, Wilmott RW, Zeitlin P, Ramsey B. Safety of aerosolized INS365 in patients with mild to moderate cystic fibrosis: results of a Phase I multi-center study. Pediatr Pulmonol 2001 Aug; 32(2):122-128.

Bennett WD, Zeman KL, Foy C, Shaffer CL, Johnson FL, Regnis JA, Sannuti A, Johnson J. Effect of aerosolized uridine 5'-triphosphate on mucociliary clearance in mild chronic bronchitis. Am J Respir Crit Care Med, 2001 Jul 15;164(2):302-306.

Mathews D, Kellerman D, Gorden J, Johnson C, Evans R. INS37217, a novel P2Y₂ receptor agonist, being developed for the treatment of cystic fibrosis: results from initial Phase 1 study in normal volunteers. Poster presented at the 24th European Cystic Fibrosis Conference. (ECFC) 2001 June 6-9; Vienna, Austria.

Foulks G, Sall K, Greenberg M, Tauber J, Donshik P, Berdy G, Sylvester R, Yerxa B, Crockett S, Kellerman D. Phase 2 dose ranging efficacy trial of INS365 ophthalmic solution, a P2Y₂ agonist, in patients with dry eye. Powerpoint presentation by Gary Foulks, MD at the The Association for Research in Vision and Ophthalmology (ARVO) 2001 Annual Meeting. 2001 April 29 - May 4; Fort Lauderdale, Florida, USA.

Yerxa BR, Gukasyan HJ, Pendergast W, Lee VHL. Ecto-metabolism & transport efficiency of P2Y receptor agonists by rabbit ocular surface epithelial cells. Poster presented at The Association for Research in Vision and Ophthalmology (ARVO) 2001 Annual Meeting. 2001 April 29 - May 4; Fort Lauderdale, Florida, USA.

Peterson WM, Venturini AE, Cowlen MS, Vezina M, Piccirilli G. Metabolism, ocular distribution, and ERG effects of INS37217, a novel P2Y₂ receptor agonist, for the treatment of retinal detachment. Poster presented at The Association for Research in Vision and Ophthalmology (ARVO) 2001 Annual Meeting. 2001 April 29 - May 4; Fort Lauderdale, Florida, USA.

Pintor J, Peral A, Hoyle C, Redick C, Douglass J, Sims I, Yerxa B. Effects of diadenosine polyphosphates on tear secretion in New Zealand white rabbits. Poster presented at The Association for Research in Vision and Ophthalmology (ARVO) 2001 Annual Meeting. 2001 April 29 - May 4; Fort Lauderdale, Florida, USA.

Meyer CH, Hotta K, Peterson WM, Toth CA, Jaffe GJ. The effects of INS37217, a P2Y₂ receptor agonist, on the reabsorption rates of subretinal fluid in a rabbit model of retinal detachment. Poster presented at The Association for Research in Vision and Ophthalmology (ARVO) 2001 Annual Meeting. 2001 April 29 - May 4; Fort Lauderdale, Florida, USA.

Li Y, Yiming M, Yerxa B, Kuang K, Fischbarg J. Effects of ouabain and quinidine on fluid movements across rabbit conjunctival epithelium. Poster presented at The Association for Research in Vision and Ophthalmology (ARVO) 2001 Annual Meeting. 2001 April 29 - May 4; Fort Lauderdale, Florida, USA.

Mundasad MV, Novack GD, Allgood VE, Evans RM, Gorden JC, Yerxa BR. Ocular safety of INS365 ophthalmic solution: A P2Y₂ agonist, in healthy subjects. J Ocular Pharmacol Ther, 2001 Apr, 17(2):173-179.

Kellerman DJ, Bennett WD, Zeman KL, Foy C, Gorden JC, Shaffer CL, Johnson FL. Dose response relationship of the P2Y₂ agonist INS365 on mucociliary clearance in smokers. Poster presented at the American Academy of Allergy, Asthma and Immunology 57th Annual Meeting. 2001 March 16-21; New Orleans, Louisiana, USA.

Evans R, Kaufman B, Kellerman D, Boyd B, Farr S, Taylor G, Warren S. Characterization of the in-vitro and in-vivo performance of two popular air-jet nebulizers. Poster presented at the American Academy of Allergy, Asthma and Immunology 57th Annual Meeting. 2001 March 16-21; New Orleans, Louisiana, USA.

Pendergast W, Yerxa BR, Douglass JG 3rd, Shaver SR, Dougherty RW, Redick CC, Sims IF, Rideout JL. Synthesis and P2Y receptor activity of a series of uridine dinucleoside 5'-polyphosphates. Bioorg Med Chem Lett, 2001 Jan 22, 11(2):157-160.

Yerxa BR. Therapeutic use of nucleotides in respiratory and ophthalmic diseases. Drug Devel Res, 2001, 52:196-201.

Yerxa BR, Mundasad M, Sylvester RN, Gorden JC, Cooper M, Kellerman DJ. Ocular safety of INS365 ophthalmic solution, a P2Y₂ agonist, in patients with mild to moderate dry eye disease. Poster presented at the Third International Conference on the Lacrimal Gland, Tear Film and Dry Eye Syndromes: Basic Science and Clinical Relevance. 2000 November 15-18; Maui, Hawaii, USA.

Yerxa BR, Douglass JG, Elena P-P, Caillaud T, Amar T, Redick CC, Peterson WM. Potency and duration of action of synthetic P2Y₂ receptor agonists on Schirmer scores in rabbits. Poster presented at the Third International Conference on the Lacrimal Gland, Tear Film and Dry Eye Syndromes: Basic Science and Clinical Relevance. 2000 November 15-18; Maui, Hawaii, USA.

Gukasyan HJ, Yerxa BR, Pendergast W, Lee, VHL. Metabolism and transport of purinergic receptor agonists in rabbit conjunctival epithelial cells. Poster presented at the Third International Conference on the Lacrimal Gland, Tear Film and Dry Eye Syndromes: Basic Science and Clinical Relevance. 2000 November 15-18; Maui, Hawaii, USA.

Zhang VZ, Sheridan L, Moyer CF, Cowlen MS, Yerxa BR. Distribution of P2Y₂ receptor mRNA in primate lung tissue by nonisotopic in situ hybridization. Poster presented at the North American Cystic Fibrosis Conference. 2000 November 9-12; Baltimore, Maryland, USA.

Dougherty RW, Pendergast W, Abraham WM, Sabater JR, Davis CW. Effects of P2Y₂ receptor agonists on cilia beat frequency in cultured human airway epithelia and on tracheal mucus velocity (TMV) in sheep. Poster presented at the North American Cystic Fibrosis Conference. (NACFC)2000 November 9-12; Baltimore, Maryland, USA.

Dougherty RW, Redick CC, Sims I, Pendergast W, Douglass J, Lang-Furr M, Stutts MJ. Effects of INS37217 on activation of recombinant human P2Y receptors and chloride secretion by dog tracheal epithelium. Poster presented at the North American Cystic Fibrosis Conference. (NACFC)2000 November 9-12; Baltimore, Maryland, USA.

Cowlen MS, Moyer CF, Sheridan L, Shaver SR, Yerxa BR. Cellular localization of P2Y₂ receptor gene expression in monkey vaginal and cervical tissue sections by non-radioisotopic in situ hybridization. Poster presented at the Female Sexual Function Forum, New Perspectives in the Management of Female Sexual Dysfunction. 2000 October 26-28; Boston, Massachusetts, USA.

Malmsjo M, Adner M, Harden TK, Pendergast W, Edvinsson L, Erlinge D. The stable pyrimidines uridine 5'-O-thiodiphosphate and uridine 5'-O-3-thiotriphosphate discriminate between the P2 receptors that mediate vascular contraction and relaxation of rat mesenteric artery. Drug Devel Res, 2000, 50(1):93 (179).

Malmsjo M, Hou M, Harden TK, Pendergast W, Pantev E, Edvinsson L, Erlinge D. Characterization of contractile P2 receptors in human coronary arteries by use of the stable pyrimidines uridine 5'-O-thiodiphosphate and uridine 5'-O-3-thiotriphosphate. J Pharmacol Exp Ther, 2000 Jun, 293(3):755:760.

Evans R, Johnson F, Kellerman D, Boyd B, Cipolla D, Farr S, Taylor G, Warren S. Aerosolized INS365 for COPD: enhanced deposition and clearance using the AER_x^® delivery system. Poster presented at the American Thoracic Society International Conference. 2000 May 5-10; Toronto, Canada.

Yerxa BR, Zhang VZ, Sheridan L, Moyer CF, Cowlen MS. Cellular localization of P2Y₂ receptor gene expression in primate ocular tissues by nonisotopic in situ hybridization. Poster presented at The Association for Research in Vision and Ophthalmology (ARVO) 2000 Annual Meeting. 2000 April 30 - May 5; Ft. Lauderdale, Florida, USA.

Mundasad MV, Yerxa BR, Allgood VE, Evans RM, Gorden JC, Novack GD. Ocular safety of INS365 ophthalmic solution, a P2Y₂ agonist, in healthy subjects. Poster presented at The Association for Research in Vision and Ophthalmology (ARVO) 2000 Annual Meeting. 2000 April 30 - May 5; Ft. Lauderdale, Florida, USA.

Erlinge D, Harden TK, Pendergast W, Baldetorp B, MÖller S, Edvinsson L, Hou M. P2Y₆ receptor mediated mitogenic effects of vascular smooth muscle cells. Drug Devel Res, 2000, 50(1):94 (182).

Krunkosky TM, Fischer BM, Martin LD, Jones N, Akley NJ, Adler KB. Effects of TNF-alpha on expression of ICAM-1 in human airway epithelial cells in vitro. Signaling pathways controlling surface and gene expression. Am J Respir Cell Mol Biol, 2000 Jun 1, 22(6):685-692.

Sabater JR, Mao YM, Shaffer C, James MK, O'Riordan TG, Abraham WM. Aerosolization of P2Y₂-receptor agonists enhances mucociliary clearance in sheep. J Appl Physiol, 1999 Dec, 87(6):2191-2196.

Johnson FL, Zeman KL, Foy CE, Shaffer CL, Bennett WD. Aerosolized UTP stimulates mucociliary clearance in smokers with mild chronic bronchitis. J Aerosol Med, 1999 Summer, 12(2):141.

Yerxa BR, Elena PP, Caillaud T, Amar T, Evans R. INS365, A P2Y₂ receptor agonist, increases Schirmer scores in albino rabbits. Poster presented at The Association for Research in Vision and Ophthalmology (ARVO) 1999 Annual Meeting. 1999 May 9-14; Ft. Lauderdale, Florida, USA.

Yerxa BR, Johnson FL. P2Y₂ receptor agonists: structure, activity and therapeutic utility. Drugs of the Future, 1999, 24(7):759-769.

Dougherty RW, Croom D, James M, Jones C, Pendergast W, Yerxa B, Abraham W, Sabater J, Davis CW, Stutts MJ. Effects of INS365, a P2Y₂ receptor agonist, on components of the mucociliary clearance system. Poster presented at the North American Cystic Fibrosis Conference. (NACFC) 1998 October 15-18; Montreal, Quebec, Canada.

Shaffer C, Jacobus K, Yerxa B, Johnson F, Griffin W, Evans R, Edgar P. INS365, a novel P2Y₂ receptor agonist and ion channel modulator for the treatment of cystic fibrosis: results from initial Phase I study. Poster presented at the North American Cystic Fibrosis Conference. (NACFC) 1998 October 15-18; Montreal, Quebec, Canada.

Siddiqi SM, Shaver SR, Pendergast W, Yerxa BR, Croom DK, Dougherty RW, James MK, Jones AC, and Rideout JL. Molecular modeling of the P2Y₂ purinoceptor and synthesis of selected ligands. Poster presented at the 6th International Symposium on Adenosine and Adenine Nucleotides. 1998 May 19-24; Ferrara, Italy.

Shaffer C, Jacobus K, Foy C, Pue C, Donohue J, Bennett W, Ye H, Graham C, Noone P, and Drutz D. Controlled clinical studies indicate that INS316 (Uridine 5'-triphosphate) a P2Y₂ receptor agonist stimulates mucociliary clearance and enhances sputum expectoration. Poster presented at the American Thoracic Society International Conference. 1998 April 24-29; Chicago, Illinois, USA.

Shaffer C, Jacobus K, Foy C, Pue C, Donohue J, Bennett W, Ye H, Graham C, Noone P, and Drutz D. Controlled clinical studies indicate that INS316 (Uridine 5'-triphosphate) a P2Y₂ receptor agonist stimulates mucociliary clearance and enhances sputum expectoration. Am J Respir Crit Care Med, 1998, 157(3):A796.

Shaver SR, Pendergast W, Siddiqi SM, Yerxa BR, Croom DK, Dougherty RW, James MK, Jones AN, and Rideout JL. 4-substituted uridine 5'-triphosphates as agonists of the P2Y₂ purinergic receptor. Nucleosides & Nucleotides, 1997, 16(7-9):1099-1102.

Shaver SR, Pendergast W, Siddiqi SM, Yerxa BR, Croom DK, Dougherty RW, James MK, Jones AN, Rideout JL. 4-Substituted uridine 5'-triphosphates as agonists of the P2Y₂ purinergic receptor. Poster presented at the Twelfth International Roundtable of Nucleosides, Nucleotides, and Their Biological Applications. 1996 September 15-19; La Jolla, California, USA.

Drutz D, Shaffer C, LaCroix K, Jacobus K, Knowles M, Bennett W, Regnis J, Hohneker K, Noone P, Davis W, Geary C, and Boucher R. Uridine 5'-Triphosphate (UTP) regulates mucociliary clearance via purinergic receptor activation. Poster presented at the Purines '96. Molecular, Pharmacological and Therapeutic Advances. 1996 July 6-9; Milan, Italy.

Pendergast W, Siddiqi SM, Rideout JL, James MK, and Dougherty RW. Stabilized uridine triphosphate analogs as agonists of the P2Y₂ purinergic receptor. Poster presented at the Purines '96. Molecular, Pharmacological and Therapeutic Advances. 1996 July 6-9; Milan, Italy.

Drutz D, Shaffer C, LaCroix K, Jacobus K, Knowles M, Bennett W, Regnis J, Hohneker K, Noone P, Davis W, Geary C, and Boucher R. Uridine 5'-triphosphate (UTP) regulates mucociliary clearance via purinergic receptor activation. Drug Devel Res, 1996, 37:185.

Pendergast W, Siddiqi SM, Rideout JL, James MK, and Dougherty RW. Stabilized uridine triphosphate analogs as agonists of the P2Y₂ purinergic receptor. Drug Devel Res, 1996, 37:133.

James MK and Shaffer CL. Pharmacologic approaches to correct the bioelectric deficits in cystic fibrosis. Expert Opinion on Investigational Drugs, 1996, 5(9):1163-1171.